Objective: To investigate plasma-free carnitine (Fc), acylcarnitine (Ac), and total carnitine
(Tc) levels in patients undergoing hemodialysis (HD), and to explore their clinical …

Purpose Carnitine deficiency is common in end-stage renal disease (ESRD) patients
receiving hemodialysis (HD) treatment. We investigated the effects of l-carnitine …

Background: Carnitine deficiency is common in patients on dialysis. Serum free carnitine
concentration is significantly lower in patients on hemodialysis (HD) than in healthy …

Background. Carnitine loss through dialysis membranes is shown to be related to the lack of
carnitine in long-term haemodialysis patients. It has been previously reported that …

Impact of hemodialysis on endogenous plasma and muscle carnitine levels in patients with
end-stage renal disease. Background End-stage renal disease (ESRD) patients undergoing …

Background: Patients on hemodialysis (HD) are known to be at risk of carnitine deficiency.
The aims of this study were to investigate the prevalence of carnitine deficiency in patients …

Carnitine has high dialyzability and is often deficient in dialysis patients. This deficiency is
treated by either intravenous (IV) or oral supplementation of carnitine. In this study, the mode …

Carnitine metabolism and the therapeutic use of carnitine has been a major area of interest
in dialysis patients. The purpose of this study was to determine whether any correlations …

L-carnitine supplementation is extensively used in patients on maintenance hemodialysis
(HD) to improve dialysis-related clinical symptoms. In a series of studies, we investigated the …

Abstract Background/Aims: Hospitalizations account for 41% of the total cost of end-stage
renal disease (ESRD) care. Carnitine deficiency is common among dialysis patients, and …